These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17196047)

  • 21. Remission in first-episode psychosis: predictor variables and symptom improvement patterns.
    Emsley R; Oosthuizen PP; Kidd M; Koen L; Niehaus DJ; Turner HJ
    J Clin Psychiatry; 2006 Nov; 67(11):1707-12. PubMed ID: 17196049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia.
    Valencia M; Fresan A; Juárez F; Escamilla R; Saracco R
    J Psychiatr Res; 2013 Dec; 47(12):1886-92. PubMed ID: 24112947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine: a multicenter, 4-week case-control study.
    Chou YH; Chiu NM; Yang TT; Feng J; Chan CC; Lee HK;
    Int Clin Psychopharmacol; 2013 Sep; 28(5):255-60. PubMed ID: 23820333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: the significance of symptoms, neuropsychological performance and cognitive biases.
    Andreou C; Roesch-Ely D; Veckenstedt R; Bohn F; Aghotor J; Köther U; Pfueller U; Moritz S
    Psychiatry Res; 2013 Dec; 210(3):729-34. PubMed ID: 23998362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
    Rovner J; Assunção S; Gargoloff P; Ibarra HS; Gasca JA; Fournais EL; Adan P; Andrades NJ; Dyachkova Y
    Vertex; 2005; 16(63):332-41. PubMed ID: 16220148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.
    Haro JM; Novick D; Bertsch J; Karagianis J; Dossenbach M; Jones PB
    Br J Psychiatry; 2011 Sep; 199(3):194-201. PubMed ID: 21881098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.
    Haynes VS; Zhu B; Stauffer VL; Kinon BJ; Stensland MD; Xu L; Ascher-Svanum H
    BMC Psychiatry; 2012 Dec; 12():222. PubMed ID: 23216976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.
    Stentebjerg-Olesen M; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Jeppesen P; Correll CU
    Eur Child Adolesc Psychiatry; 2015 Dec; 24(12):1485-96. PubMed ID: 26032132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
    Silva de Lima M; de Jesus Mari J; Breier A; Maria Costa A; Pondé de Sena E; Hotopf M
    J Clin Psychiatry; 2005 Jul; 66(7):831-8. PubMed ID: 16013897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
    Lasser RA; Bossie CA; Gharabawi GM; Kane JM
    Schizophr Res; 2005 Sep; 77(2-3):215-27. PubMed ID: 15908183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Heuser I; Maier W; Klosterkötter J; Falkai P; Schlösser R; Schmitt A; Riedel M; Klingberg S; Köpcke W; Ohmann C; Möller HJ
    Schizophr Res; 2014 Feb; 152(2-3):478-86. PubMed ID: 23643327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.
    Dikeos D; Badr MG; Yang F; Pesek MB; Fábián Z; Tapia-Paniagua G; Hudiţă C; Okasha T; D'yachkova Y; Harrison G; Treuer T
    World J Biol Psychiatry; 2010 Jun; 11(4):667-76. PubMed ID: 20334575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The concurrent and predictive validity of symptomatic remission criteria in first-episode schizophrenia.
    Chang WC; Chan TC; Chen ES; Hui CL; Wong GH; Chan SK; Lee EH; Chen EY
    Schizophr Res; 2013 Jan; 143(1):107-15. PubMed ID: 23151398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.